TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25204091

Group type: EXPERIMENTAL
Intervention: Anorexia readiness syndrome (ARS) group (N=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no signs of ARS) (N=23)
Number of subjects: 46
Study: 23099809

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with 5‐FU/LEV
Number of subjects: 335

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 335
Study: 21057441

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with a short reperfusion phase (2 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17955458

Group type: EXPERIMENTAL
Intervention: Polymorphisms in the CHRNA4 gene tested for interactions with prenatal smoking exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous interactions for the DRD4 and DAT1 genes with prenatal smoking exposure
Number of subjects: 0
Study: 17653259

Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 2 mg/d
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 4 mg/d
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 8 mg/d
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 16 mg/d
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 237
Study: 15277146

Group type: EXPERIMENTAL
Intervention: 3 g c9,t11 CLA/d
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 25
Study: 11023084

Group type: EXPERIMENTAL
Intervention: Ivermectin, 6 mg in a single dose
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Albendazole, 400 mg/day for 3 days
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate, 5 mg/kg/day for 3 days
Number of subjects: 211
Study: 9342643

Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease
Number of subjects: 36

Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 36
Study: 1337525

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: TMP/SMX (160/800 mg orally twice daily)
Number of subjects: 126
Study: 3159759

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 37
Study: 31405377

Group type: EXPERIMENTAL
Intervention: LSIL, HSIL, CSCC
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (healthy females)
Number of subjects: 432
Study: 29670895

Group type: EXPERIMENTAL
Intervention: Glasses and Occlu-pad
Number of subjects: 46

Group type: COMPARATOR
Intervention: Glasses only
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Occlu-pad compliance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Occlu-pad training time
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Compliance rate comparison
Number of subjects: 46
Study: 26259981

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intensive medical management (IMM)
Number of subjects: 30
Study: 25262435

Group type: EXPERIMENTAL
Intervention: Print-delivered basic (PB)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Print-delivered environmental (PE)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Web-based environmental (WE)
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 1729
Study: 22241602

Group type: EXPERIMENTAL
Intervention: Granisetron 40 μg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Granisetron 10 μg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Granisetron 10 μg/kg and 40 μg/kg
Number of subjects: 16
Study: 19849695

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dermatologist
Number of subjects: 160
Study: 17973851

Group type: EXPERIMENTAL
Intervention: Dinucleotide repeats for carrier detection and prenatal diagnosis
Number of subjects: 85
Study: 15386762

Group type: EXPERIMENTAL
Intervention: Group therapy for women with recently diagnosed primary breast cancer
Number of subjects: 352
Study: 12214257

Group type: EXPERIMENTAL
Intervention: Intervention group (anticipation of a blood test)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no anticipation of a blood test)
Number of subjects: 213
Study: 9527733

Group type: EXPERIMENTAL
Intervention: Thiopentone induction and isoflurane maintenance
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Thiopentone induction and isoflurane maintenance plus ondansetron 5 mg x m(‐2) i.v.
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance plus lignocaine 2 mg x kg(‐1) i.v.
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 157

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 157
Study: 7608323

Group type: EXPERIMENTAL
Intervention: Rivastatin 300 micrograms once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 21
Study: 2515159

Group type: EXPERIMENTAL
Intervention: Daonil (product A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucomid (product B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 16
Study: 194679

Group type: EXPERIMENTAL
Intervention: L phenylalanine mustard (L PAM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L phenylalanine mustard (L PAM) plus 5 fluorouracil (5 FU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: L PAM
Number of subjects: 100
Study: 31779585

Group type: EXPERIMENTAL
Intervention: EBV seroprevalence in 11-14 year olds (60.4%)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Ethnicity (other ethnicity versus white individuals)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 732
Study: 30527256

Group type: EXPERIMENTAL
Intervention: Okinawan-based Nordic (O-BN) diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (non-diabetic subjects)
Number of subjects: 19
Study: 26699597

Group type: EXPERIMENTAL
Intervention: High-degree AV block
Number of subjects: 29677

Group type: EXPERIMENTAL
Intervention: Asystole
Number of subjects: 29677

Group type: EXPERIMENTAL
Intervention: Electromechanical dissociation (EMD)
Number of subjects: 29677

Group type: EXPERIMENTAL
Intervention: Pacemaker insertion
Number of subjects: 29677

Group type: EXPERIMENTAL
Intervention: Factors associated with high-degree AV block
Number of subjects: 29677

Group type: EXPERIMENTAL
Intervention: Factors associated with asystole or EMD
Number of subjects: 29677
Study: 25179977

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 67
Study: 22154118

Group type: EXPERIMENTAL
Intervention: FEC-PH (4 cycles of FEC followed by 4 cycles of trastuzumab and 12 weekly doses of paclitaxel 80 mg/m(2))
Number of subjects: 102

Group type: COMPARATOR
Intervention: FEC-DH (4 cycles of FEC followed by 4 cycles of trastuzumab and 4 cycles of docetaxel 75 mg/m(2))
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FEC-PH in HR(-) tumors
Number of subjects: 102

Group type: COMPARATOR
Intervention: FEC-DH in HR(-) tumors
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FEC-PH in HR(+) tumors
Number of subjects: 102

Group type: COMPARATOR
Intervention: FEC-DH in HR(+) tumors
Number of subjects: 102
Study: 20706089

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 17613598

Group type: EXPERIMENTAL
Intervention: New clinical classification system for MS (monofocal vs multifocal)
Number of subjects: 487
Study: 16305563

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg/1.5 mL gel solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Misoprostol 400 mcg/1.5 mL gel solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 60
Study: 12819295

Group type: EXPERIMENTAL
Intervention: Early treatment with epoetin beta (NeoRecormon) administered subcutaneously aiming for a target Hb level of 13‐15 g/dl.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Late treatment with epoetin beta (NeoRecormon) administered subcutaneously starting once Hb level declines to below 10.5 g/dl (target Hb level 10.5‐11.5 g/dl).
Number of subjects: 600
Study: 10395120

Group type: EXPERIMENTAL
Intervention: Omeprazole (Losec) administered intravenously
Number of subjects: 0
Study: 8905503

Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Mailed reminder plus nurse counseling
Number of subjects: 970

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 970
Study: 1863026

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide (12 mg over 12 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus therapy of bumetanide (two 6 mg doses separated by 6 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus therapy of bumetanide
Number of subjects: 8
Study: 6756931

Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during metoprolol medication
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during acebutolol medication
Number of subjects: 8

Group type: COMPARATOR
Intervention: Metoprolol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Acebutolol 400 mg
Number of subjects: 8
Study: 31772695

Group type: EXPERIMENTAL
Intervention: LLLT + self-ligating (SL) bracket
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LLLT + conventional (Conv.) bracket
Number of subjects: 32

Group type: COMPARATOR
Intervention: non-LLLT + SL bracket
Number of subjects: 32

Group type: COMPARATOR
Intervention: non-LLLT + Conv. bracket
Number of subjects: 32
Study: 28973094

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 28
Study: 26028054

Group type: EXPERIMENTAL
Intervention: ToM training (ToM Strange Stories and ToM Animations)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 23795857

Group type: EXPERIMENTAL
Intervention: CHERRY programme (Choosing Healthy Eating when Really Young)
Number of subjects: 394
Study: 23228869

Group type: EXPERIMENTAL
Intervention: Temporal artery temperature measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal temperature measurement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 60
Study: 20716996

Group type: EXPERIMENTAL
Intervention: Baseline infection with STIs (chlamydial, gonococcal, or trichomonal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No STIs at baseline
Number of subjects: 0
Study: 17569681

Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both interventions (biphasic and monophasic)
Number of subjects: 44
Study: 16291467

Group type: EXPERIMENTAL
Intervention: Delphi consensus method
Number of subjects: 154
Study: 11899174

Group type: EXPERIMENTAL
Intervention: Cold crystalloid perfusion (4 degrees C Ringer's lactate solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic blood perfusion
Number of subjects: 30
Study: 9645457

Group type: EXPERIMENTAL
Intervention: Granisetron (0.5 mg i.v. bolus + continuous infusion of 0.04 mg/h for 7 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ondansetron (8 mg i.v. bolus + continuous infusion of 1 mg/h for 7 days)
Number of subjects: 48
Study: 8174846

Group type: EXPERIMENTAL
Intervention: ANP (0.04 micrograms.kg‐1.min‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle (50 ml saline)
Number of subjects: 22
Study: 3237194

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (3,680 mIU in 45 min)
Number of subjects: 20
Study: 30665386

Group type: EXPERIMENTAL
Intervention: Patients with diabetes or hypertension
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Residents in rural Walungu health zone
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Female respondents
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Older respondents
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Respondents from the poorest socioeconomic status
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Respondents who had an acute illness 30 days prior to the interview
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Respondents who are informally employed
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Petty traders/farmers
Number of subjects: 1609
Study: 29781459

Group type: EXPERIMENTAL
Intervention: FCG support intervention
Number of subjects: 20
Study: 27429596

Group type: EXPERIMENTAL
Intervention: Pre-workout supplement (SUP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline (BA)
Number of subjects: 13
Study: 24550162

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: EUS-guided core biopsy needle (FNB)
Number of subjects: 32
Study: 21300729

Group type: EXPERIMENTAL
Intervention: Pumiced for 10 seconds and pre-etched for 5 seconds with 37% phosphoric acid before bonding with SEP (Transbond Plus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pumiced for 10 seconds before bonding
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-etched for 5 seconds before bonding
Number of subjects: 60

Group type: COMPARATOR
Intervention: No mechanical or chemical preparation before bonding
Number of subjects: 60
Study: 19114685

Group type: EXPERIMENTAL
Intervention: Panitumumab added to bevacizumab and chemotherapy (oxaliplatin-based)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Control (bevacizumab and chemotherapy without panitumumab)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Panitumumab added to bevacizumab and chemotherapy (irinotecan-based)
Number of subjects: 1053
Study: 17709802

Group type: EXPERIMENTAL
Intervention: HDC/IL-2/IFN
Number of subjects: 241

Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 241
Study: 15990651

Group type: EXPERIMENTAL
Intervention: Autologous fibrin tissue adhesive
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no fibrin tissue adhesive)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Commercial fibrin tissue adhesive
Number of subjects: 39
Study: 12063437

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin treatment for patients with antiphospholipid antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autoimmune factors as markers
Number of subjects: 0
Study: 9676903

Group type: EXPERIMENTAL
Intervention: Epithelial removal followed by excimer laser ablation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Epithelial removal only
Number of subjects: 56
Study: 10150265

Group type: EXPERIMENTAL
Intervention: 0.2% bromochlorophene toothpaste
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both BCP and placebo toothpastes
Number of subjects: 32
Study: 3291523

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin injection therapy
Number of subjects: 12
Study: 8022437

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg, 4 ml)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (4 ml nebulized normal saline)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 371664

Group type: EXPERIMENTAL
Intervention: 5 mg prostaglandin E2 (PGE2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31799875

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 39
Study: 31608829

Group type: EXPERIMENTAL
Intervention: Complete sleep deprivation (DEP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (PART)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal sleep (CON)
Number of subjects: 10
Study: 28131004

Group type: EXPERIMENTAL
Intervention: Immediate health benefits information
Number of subjects: 110

Group type: COMPARATOR
Intervention: Long-term health benefits information
Number of subjects: 110
Study: 25552408

Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 0
Study: 23980808

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 2349
Study: 21861914

Group type: EXPERIMENTAL
Intervention: NIPPV + PR
Number of subjects: 66

Group type: COMPARATOR
Intervention: PR
Number of subjects: 66
Study: 19482279

Group type: EXPERIMENTAL
Intervention: 6-mm Zilver stent
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 10-mm Zilver stent
Number of subjects: 241

Group type: COMPARATOR
Intervention: 10-mm Wallstent
Number of subjects: 241
Study: 17223872

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 9
Study: 15643131

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily for 16 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily for 16 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls (n = 32)
Number of subjects: 49
Study: 11881123

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once-daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9562277

Group type: EXPERIMENTAL
Intervention: Comfeel (occlusive dressing)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Mepore (conventional dressing)
Number of subjects: 73
Study: 8173308

Group type: EXPERIMENTAL
Intervention: 20% long-chain triglyceride emulsion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20% medium-chain triglyceride emulsion
Number of subjects: 29

Group type: COMPARATOR
Intervention: 20% glucose infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10% long-chain triglyceride emulsion
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10% medium-chain triglyceride emulsion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 150% of calculated daily calorie intake
Number of subjects: 29
Study: 10312366

Group type: EXPERIMENTAL
Intervention: Exogenous estrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study: 31996604

Group type: EXPERIMENTAL
Intervention: Prior TBI
Number of subjects: 1148

Group type: COMPARATOR
Intervention: No prior TBI
Number of subjects: 1148
Study: 30618101

Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 600 μg misoprostol
Number of subjects: 453
Study: 28783372

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 2% lavender essential oil for 70 minutes every other week for 20 weeks (10 times total)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 2% lavender essential oil
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 52
Study: 26067435

Group type: EXPERIMENTAL
Intervention: Combination treatment matching the biomarker indication
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination treatment mismatching the biomarker indication
Number of subjects: 30
Study: 22528470

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) program
Number of subjects: 223

Group type: COMPARATOR
Intervention: Health-related educational lectures (Control)
Number of subjects: 223
Study: 22254084

Group type: EXPERIMENTAL
Intervention: Micronutrient fortified yogurt with additional probiotic Lactobacillus rhamnosus GR‐1
Number of subjects: 112

Group type: COMPARATOR
Intervention: Micronutrient fortified yogurt without additional probiotic
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups (micronutrient yogurt with and without probiotics)
Number of subjects: 112
Study: 19344858

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16856776

Group type: EXPERIMENTAL
Intervention: FluMist immunizations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no FluMist immunizations)
Number of subjects: 0
Study: 12885805

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IFNalpha2b plus IL-2
Number of subjects: 225
Study: 9890581

Group type: EXPERIMENTAL
Intervention: Nonviolent criminal victimization
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Violent criminal victimization
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Substance use and transient living conditions
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Perceived vulnerability to victimization
Number of subjects: 331
Study: 8983921

Group type: EXPERIMENTAL
Intervention: Exercise test at 10 a.m.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise test at 5 p.m.
Number of subjects: 15
Study: 1664869

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3; alkaline), dosage: 0.3 g kg‐1 body mass, 2.5 h prior to exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl; placebo), dosage: 1.5 g total, 2.5 h prior to exercise
Number of subjects: 7